IGFBP-2 - taking the lead in growth, metabolism and cancer

Journal of Cell Communication and Signaling

Volumn 9, Issue 2, 2015, Pages 125-142

  Yau, Steven W ^a,b   Azar, Walid J ^c   Sabin, Matthew A ^a,b   Werther, George A ^a,b   Russo, Vincenzo C ^a,b  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Colon cancer; Diabetes; Growth; IGF system; IGFBP 2; Leukaemia; Lung cancer; Metabolism; Obesity

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTEGRIN RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; PROTEIN PATCHED 1; PROTEOGLYCAN; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 2;

ARTICLE; BODY COMPOSITION; BONE GROWTH; BONE TURNOVER; CELL SURFACE; COLON CANCER; DIABETES MELLITUS; DISEASE ASSOCIATION; EXTRACELLULAR MATRIX; GENE; HUMAN; IGFBP2 GENE; INSULIN SENSITIVITY; INTRANUCLEAR SPACE; LEUKEMIA; LUNG CANCER; METABOLIC REGULATION; NEOPLASM; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 84930542548     PISSN: 18739601     EISSN: 1873961X     Source Type: Journal    
DOI: 10.1007/s12079-015-0261-2     Document Type: Article

References (186)

1. Zapf J, Froesch ER (1986) Insulin-like growth factors/somatomedins: structure, secretion, biological actions and physiological role. Horm Res 24:121–130
2. Daughaday WH, Rotwein P (1989) Insulin-like growth factors I and II. Peptide messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 10:68–91
3. Han VK, D’Ercole AJ, Lund PK (1987) Cellular localization of somatomedin (insulin-like growth factor) messenger RNA in the human fetus. Science 236:193–197
4. Murphy LJ, Bell GI, Friesen HG (1987) Tissue distribution of insulin-like growth factor I and II messenger ribonucleic acid in the adult rat. Endocrinology 120:1279–1282
5. Sepp-Lorenzino L (1998) Structure and function of the insulin-like growth factor I receptor. Breast Cancer Res Treat 47:235–253
6. Milazzo G, Yip CC, Maddux BA, Vigneri R, Goldfine ID (1992) High-affinity insulin binding to an atypical insulin-like growth factor-I receptor in human breast cancer cells. J Clin Investig 89:899–908
7. Moxham CP, Duronio V, Jacobs S (1989) Insulin-like growth factor I receptor beta-subunit heterogeneity. Evidence for hybrid tetramers composed of insulin- like growth factor I and insulin receptor heterodimers. J Biol Chem 264:13238–13244
8. Siddle K, Soos MA, Field CE, Nave BT (1994) Hybrid and atypical insulin/insulin-like growth factor I receptors. Horm Res 41(Suppl 2):56–64
9. Sakano K, Enjoh T, Numata F, Fujiwara H, Marumoto Y, Higashihashi N, Sato Y, Perdue JF, Fujita-Yamaguchi Y (1991) The design, expression, and characterization of human insulin- like growth factor II (IGF-II) mutants specific for either the IGF-II/cation-independent mannose 6-phosphate receptor or IGF-I receptor. J Biol Chem 266:20626–20635
10. Braulke T (1999) Type-2 IGF receptor: a multi-ligand binding protein. Horm Metab Res 31:242–246
11. Firth SM, Baxter RC (2002) Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23:824–854
12. Twigg SM, Kiefer MC, Zapf J, Baxter RC (2000) A central domain binding site in insulin-like growth factor binding protein-5 for the acid-labile subunit. Endocrinology 141:454–457
13. Galea CA, Mobli M, McNeil KA, Mulhern TD, Wallace JC, King GF, Forbes BE, Norton RS (2012) Insulin-like growth factor binding protein-2: NMR analysis and structural characterization of the N-terminal domain. Biochimie 94:608–616
14. Forbes BE, Turner D, Hodge SJ, McNeil KA, Forsberg G, Wallace JC (1998) Localization of an insulin-like growth factor (IGF) binding site of bovine IGF binding protein-2 using disulfide mapping and deletion mutation analysis of the C-terminal domain. J Biol Chem 273:4647–4652
15. Ho PJ, Baxter RC (1997a) Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin Endocrinol 46:333–342
16. Russo VC, Rekaris G, Baker NL, Bach LA, Werther GA (1999) Basic fibroblast growth factor induces proteolysis of secreted and cell membrane-associated insulin-like growth factor binding protein-2 in human neuroblastoma cells. Endocrinology 140:3082–3090
17. Graham ME, Kilby DM, Firth SM, Robinson PJ, Baxter RC (2007) The in vivo phosphorylation and glycosylation of human insulin-like growth factor-binding protein-5. Mol Cell Proteomics 6:1392–1405
18. Coverley JA, Baxter RC (1997) Phosphorylation of insulin-like growth factor binding proteins. Mol Cell Endocrinol 128:1–5
19. Daza DO, Sundström G, Bergqvist CA, Duan C, Larhammar D (2011) Evolution of the insulin-like growth factor binding protein (IGFBP) family. Endocrinology 152:2278–2289
20. Song SW, Fuller GN, Khan A, Kong S, Shen W, Taylor E, Ramdas L, Lang FF, Zhang W (2003) IIp45, an insulin-like growth factor binding protein 2 (IGFBP-2) binding protein, antagonizes IGFBP-2 stimulation of glioma cell invasion. Proc Natl Acad Sci U S A 100:13970–13975
21. Frommer KW, Reichenmiller K, Schutt BS, Hoeflich A, Ranke MB, Dodt G, Elmlinger MW (2006) IGF-independent effects of IGFBP-2 on the human breast cancer cell line Hs578T. J Mol Endocrinol 37:13–23
22. Pereira JJ, Meyer T, Docherty SE, Reid HH, Marshall J, Thompson EW, Rossjohn J, Price JT (2004) Bimolecular interaction of insulin-like growth factor (IGF) binding protein-2 with alphavbeta3 negatively modulates IGF-I-mediated migration and tumor growth. Cancer Res 64:977–984
23. Perks CM, Vernon EG, Rosendahl AH, Tonge D, Holly JM (2007) IGF-II and IGFBP-2 differentially regulate PTEN in human breast cancer cells. Oncogene 26:5966–5972
24. Foulstone EJ, Zeng L, Perks CM, Holly JM (2013) Insulin-like growth factor binding protein 2 (IGFBP-2) promotes growth and survival of breast epithelial cells: novel regulation of the estrogen receptor. Endocrinology
25. Russo VC, Schutt BS, Andaloro E, Ymer SI, Hoeflich A, Ranke MB, Bach LA, Werther GA (2005) Insulin-like growth factor binding protein-2 binding to extracellular matrix plays a critical role in neuroblastoma cell proliferation, migration, and invasion. Endocrinology 146:4445–4455
26. Shen X, Xi G, Maile LA, Wai C, Rosen CJ, Clemmons DR (2012) Insulin-like growth factor binding protein-2 functions coordinately with receptor protein tyrosine phosphatase beta and the IGF-I receptor to regulate IGF-I-stimulated signaling. Mol Cell Biol 32:4116–4130
27. Kuang Z, Yao S, Keizer DW, Wang CC, Bach LA, Forbes BE, Wallace JC, Norton RS (2006) Structure, dynamics and heparin binding of the C-terminal domain of insulin-like growth factor-binding protein-2 (IGFBP-2). J Mol Biol 364:690–704
28. Besnard V, Corroyer S, Trugnan G, Chadelat K, Nabeyrat E, Cazals V, Clement A (2001) Distinct patterns of insulin-like growth factor binding protein (IGFBP)-2 and IGFBP-3 expression in oxidant exposed lung epithelial cells. Biochim Biophys Acta (BBA) Mol Cell Res 1538:47–58
29. Terrien X, Bonvin E, Corroyer S, Tabary O, Clement A, Henrion Caude A (2005) Intracellular colocalization and interaction of IGF-binding protein-2 with the cyclin-dependent kinase inhibitor p21CIP1/WAF1 during growth inhibition. Biochem J 392:457–465
30. Miyako K, Cobb LJ, Francis M, Huang A, Peng B, Pintar JE, Ariga H, Cohen P (2009) PAPA-1 Is a nuclear binding partner of IGFBP-2 and modulates its growth-promoting actions. Mol Endocrinol 23:169–175
31. Azar WJ, Azar SH, Higgins S, Hu JF, Hoffman AR, Newgreen DF, Werther GA, Russo VC (2011) IGFBP-2 enhances VEGF gene promoter activity and consequent promotion of angiogenesis by neuroblastoma cells. Endocrinology 152:3332–3342
32. Azar WJ, Zivkovic S, Werther GA, Russo VC (2014) IGFBP-2 nuclear translocation is mediated by a functional NLS sequence and is essential for its pro-tumorigenic actions in cancer cells. Oncogene 33:578–588
33. Schedlich LJ, Le Page SL, Firth SM, Briggs LJ, Jans DA, Baxter RC (2000) Nuclear import of insulin-like growth factor-binding protein-3 and -5 is mediated by the importin beta subunit. J Biol Chem 275:23462–23470
34. Iosef C, Gkourasas T, Jia CY, Li SS, Han VK (2008) A functional nuclear localization signal in insulin-like growth factor binding protein-6 mediates its nuclear import. Endocrinology 149:1214–1226
35. Chelsky D, Ralph R, Jonak G (1989) Sequence requirements for synthetic peptide-mediated translocation to the nucleus. Mol Cell Biol 9:2487–2492
36. Pintar JE, Cerro JA, Wood TL (1996) Genetic approaches to the function of insulin-like growth factor- binding proteins during rodent development. Horm Res 45:172–177
37. Wood TL, Rogler LE, Czick ME, Schuller AG, Pintar JE (2000) Selective alterations in organ sizes in mice with a targeted disruption of the insulin-like growth factor binding protein-2 gene. Mol Endocrinol 14:1472–1482
38. Chen TL, Chang LY, DiGregorio DA, Perlman AJ, Huang YF (1993) Growth factor modulation of insulin-like growth factor-binding proteins in rat osteoblast-like cells. Endocrinology 133:1382–1389
39. Palermo C, Manduca P, Gazzerro E, Foppiani L, Segat D, Barreca A (2004) Potentiating role of IGFBP-2 on IGF-II-stimulated alkaline phosphatase activity in differentiating osteoblasts. Am J Physiol Endocrinol Metab 286:E648–E657
40. Wang E, Wang J, Chin E, Zhou J, Bondy CA (1995) Cellular patterns of insulin-like growth factor system gene expression in murine chondrogenesis and osteogenesis. Endocrinology 136:2741–2751
41. Conover CA, Johnstone EW, Turner RT, Evans GL, John Ballard F, Doran PM, Khosla S (2002) Subcutaneous administration of insulin-like growth factor (IGF)-II/IGF binding protein-2 complex stimulates bone formation and prevents loss of bone mineral density in a rat model of disuse osteoporosis. Growth Hormon IGF Res 12:178–183
42. Fisher MC, Meyer C, Garber G, Dealy CN (2005) Role of IGFBP2, IGF-I and IGF-II in regulating long bone growth. Bone 37:741–750
43. DeMambro VE, Clemmons DR, Horton LG, Bouxsein ML, Wood TL, Beamer WG, Canalis E, Rosen CJ (2008) Gender-specific changes in bone turnover and skeletal architecture in Igfbp-2-null mice. Endocrinology 149:2051–2061
44. Kawai M, Breggia AC, DeMambro VE, Shen X, Canalis E, Bouxsein ML, Beamer WG, Clemmons DR, Rosen CJ (2011) The heparin-binding domain of IGFBP-2 has IGF binding-independent biologic activity in the growing skeleton. J Biol Chem 286:14670–14680
45. DeMambro VE, Maile L, Wai C, Kawai M, Cascella T, Rosen CJ, Clemmons D (2012) Insulin-like growth factor-binding protein-2 is required for osteoclast differentiation. J Bone Miner Res 27:390–400
46. Xi G, Wai C, DeMambro V, Rosen CJ, Clemmons DR (2014) IGFBP-2 directly stimulates osteoblast differentiation. J Bone Miner Res 29:2427–2438
47. Hoeflich A, Wu M, Mohan S, Foll J, Wanke R, Froehlich T, Arnold GJ, Lahm H, Kolb HJ, Wolf E (1999) Overexpression of insulin-like growth factor-binding protein-2 in transgenic mice reduces postnatal body weight gain. Endocrinology 140:5488–5496
48. Hoeflich A, Nedbal S, Blum WF, Erhard M, Lahm H, Brem G, Kolb HJ, Wanke R, Wolf E (2001) Growth inhibition in giant growth hormone transgenic mice by overexpression of insulin-like growth factor-binding protein-2. Endocrinology 142:1889–1898
49. Russo VC, Bach LA, Werther GA (1995) Cell membrane association of insulin-like growth factor binding protein-2 (IGFBP-2) in the rat brain olfactory bulb. Prog Growth Factor Res 6:329–336
50. Rehfeldt C, Renne U, Sawitzky M, Binder G, Hoeflich A (2010) Increased fat mass, decreased myofiber size, and a shift to glycolytic muscle metabolism in adolescent male transgenic mice overexpressing IGFBP-2. Am J Physiol Endocrinol Metab 299:E287–E298
51. Eckstein F, Pavicic T, Nedbal S, Schmidt C, Wehr U, Rambeck W, Wolf E, Hoeflich A (2002) Insulin-like growth factor-binding protein-2 (IGFBP-2) overexpression negatively regulates bone size and mass, but not density, in the absence and presence of growth hormone/IGF-I excess in transgenic mice. Anat Embryol (Berlin) 206:139–148
52. Hoeflich A, Schmidt P, Foll J, Rottmann O, Weber MM, Kolb HJ, Pirchner F, Wolf E (1998) Altered growth of mice divergently selected for body weight is associated with complex changes in the growth hormone/insulin-like growth factor system. Growth Hormon IGF Res 8:113–123
53. Barrios V, Buno M, Pozo J, Munoz MT, Argente J (2000) Insulin-like growth factor-binding protein-2 levels in pediatric patients with growth hormone deficiency, eating disorders and acute lymphoblastic leukemia. Horm Res 53:221–227
54. Hall K, Lundin G, Povoa G (1988) Serum levels of the low molecular weight form of insulin-like growth factor binding protein in healthy subjects and patients with growth hormone deficiency, acromegaly and anorexia nervosa. Acta Endocrinol (Copenh) 118:321–326
55. Hotta M, Fukuda I, Sato K, Hizuka N, Shibasaki T, Takano K (2000) The relationship between bone turnover and body weight, serum insulin-like growth factor (IGF) I, and serum IGF-binding protein levels in patients with anorexia nervosa. J Clin Endocrinol Metab 85:200–206
56. Wheatcroft SB, Kearney MT, Shah AM, Ezzat VA, Miell JR, Modo M, Williams SCR, Cawthorn WP, Medina-Gomez G, Vidal-Puig A, Sethi JK, Crossey PA (2007a) IGF-binding protein-2 protects against the development of obesity and insulin resistance. Diabetes 56:285–294
57. Hedbacker K, Birsoy K, Wysocki RW, Asilmaz E, Ahima RS, Farooqi IS, Friedman JM (2010) Antidiabetic effects of IGFBP2, a leptin-regulated gene. Cell Metab 11:11–22
58. Claudio M, Benjamim F, Riccardo B, Massimiliano C, Francesco B, Luciano C (2010a) Adipocytes IGFBP-2 expression in prepubertal obese children. Obesity (Silver Spring) 18:2055–2057
59. Ballerini MG, Ropelato MG, Domene HM, Pennisi P, Heinrich JJ, Jasper HG (2004) Differential impact of simple childhood obesity on the components of the growth hormone-insulin-like growth factor (IGF)-IGF binding proteins axis. J Pediatr Endocrinol Metab 17:749–757
60. Frystyk J, Skjaerbaek C, Vestbo E, Fisker S, Orskov H (1999) Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes Metab Res Rev 15:314–322
61. Levitt RJ, Georgescu M-M, Pollak M (2005) PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2. Biochem Biophys Res Commun 336:1056–1061
62. Mehrian-Shai R, Chen CD, Shi T, Horvath S, Nelson SF, Reichardt JK, Sawyers CL (2007) Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci U S A 104:5563–5568
63. Martin JL, Baxter RC (2007) Expression of insulin-like growth factor binding protein-2 by MCF-7 breast cancer cells is regulated through the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway. Endocrinology 148:2532–2541
64. Dean SJR, Perks CM, Holly JMP, Bhoo-Pathy N, Looi L-M, Mohammed NAT, Mun K-S, Teo S-H, Koobotse MO, Yip C-H, Rhodes A (2014) Loss of PTEN expression is associated with IGFBP2 expression, younger age, and late stage in triple-negative breast cancer. Am J Clin Pathol 141:323–333
65. Grimberg A, Coleman CM, Shi Z, Burns TF, MacLachlan TK, Wang W, El-Deiry WS (2006) Insulin-like growth factor factor binding protein-2 is a novel mediator of p53 inhibition of insulin-like growth factor signaling. Cancer Biol Ther 5:1408–1414
66. Villani RM, Adolphe C, Palmer J, Waters MJ, Wainwright BJ (2010) Patched1 inhibits epidermal progenitor cell expansion and basal cell carcinoma formation by limiting Igfbp2 activity. Cancer Prev Res 3:1222–1234
67. Rao G, Pedone CA, Valle LD, Reiss K, Holland EC, Fults DW (2004) Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice. Oncogene 23:6156–6162
68. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL (1999) Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res 59:3915–3918
69. Harris AL (2002) Hypoxia–a key regulatory factor in tumour growth. Nat Rev Cancer 2:38–47
70. Semenza GL (1999) Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 15:551–578
71. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721–732
72. Poomthavorn P, Wong SHX, Higgins S, Werther GA, Russo VC (2009) Activation of a prometastatic gene expression program in hypoxic neuroblastoma cells. Endocr Relat Cancer 16:991–1004
73. Matsumoto T, Gargosky SE, Iwasaki K, Rosenfeld RG (1996) Identification and characterization of insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), and IGFBP proteases in human synovial fluid. J Clin Endocrinol Metab 81:150–155
74. Ishikawa K, Ohe Y, Tatemoto K (1995) Synthesis and secretion of insulin-like growth factor (IGF)-II and IGF binding protein-2 by cultivated brain meningeal cells. Brain Res 697:122–129
75. Mark S, Kübler B, Höning S, Oesterreicher S, John H, Braulke T, Forssmann W-G, Ständker L (2005) Diversity of human insulin-like growth factor (IGF) binding protein-2 fragments in plasma: primary structure, IGF-binding properties, and disulfide bonding pattern†. Biochemistry 44:3644–3652
76. Ho PJ, Baxter RC (1997b) Characterization of truncated insulin-like growth factor-binding protein-2 in human milk. Endocrinology 138:3811–3818
77. Giudice LC, Farrell EM, Pham H, Lamson G, Rosenfeld RG (1990) Insulin-like growth factor binding proteins in maternal serum throughout gestation and in the puerperium: effects of a pregnancy-associated serum protease activity. J Clin Endocrinol Metab 71:806–816
78. Pucilowska JB, Davenport ML, Kabir I, Clemmons DR, Thissen JP, Butler T, Underwood LE (1993) The effect of dietary protein supplementation on insulin-like growth factors (IGFs) and IGF-binding proteins in children with shigellosis. J Clin Endocrinol Metab 77:1516–1521
79. Brandt K, Lundell K, Brismar K (2011) Neutrophil-derived azurocidin cleaves insulin-like growth factor-binding protein-1, −2 and −4. Growth Hormon IGF Res 21:167–173
80. DeGraff DJ, Malik M, Chen Q, Miyako K, Rejto L, Aguiar AA, Bancroft DRE, Cohen P, Sikes RA (2007) Hormonal regulation of IGFBP-2 proteolysis is attenuated with progression to androgen insensitivity in the LNCaP progression model. J Cell Physiol 213:261–268
81. Russo VC, Andaloro E, Fornaro SA, Najdovska S, Newgreen DF, Bach LA, Werther GA (2004) Fibroblast growth factor-2 over-rides insulin-like growth factor-I induced proliferation and cell survival in human neuroblastoma cells. J Cell Physiol 199:371–380
82. Hoeflich A, Reisinger R, Schuett BS, Elmlinger MW, Russo VC, Vargas GA, Jehle PM, Lahm H, Renner-Muller I, Wolf E (2004) Peri/nuclear localization of intact insulin-like growth factor binding protein-2 and a distinct carboxyl-terminal IGFBP-2 fragment in vivo. Biochem Biophys Res Commun 324:705–710
83. Si M, Nakamura M, Yano K, Ishii G, Hasebe T, Endoh Y, Sangai T, Maeda H, Shi-chuang Z, Chiba T, Ochiai A (2007) Matrix metalloproteinase-7 triggers the matricrine action of insulin-like growth factor-II via proteinase activity on insulin-like growth factor binding protein 2 in the extracellular matrix. Cancer Sci 98:685–691
84. Sunderic M, Miljus G, Nedic O (2013) Interaction of insulin-like growth factor-binding protein 2 with alpha2-macroglobulin in the circulation. Protein J 32:138–142
85. Gerard N, Delpuech T, Oxvig C, Overgaard M, Monget P (2004) Proteolytic degradation of IGF-binding protein (IGFBP)-2 in equine ovarian follicles: involvement of pregnancy-associated plasma protein-A (PAPP-A) and association with dominant but not subordinated follicles. J Endocrinol 182:457–466
86. Qin X, Wergedal JE, Rehage M, Tran K, Newton J, Lam P, Baylink DJ, Mohan S (2006) Pregnancy-associated plasma protein-A increases osteoblast proliferation in vitro and bone formation in vivo. Endocrinology 147:5653–5661
87. Ruoslahti E (1996) RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 12:697–715
88. Schutt B, Langkamp M, Rauschnabel U, Ranke M, Elmlinger M (2004) Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J Mol Endocrinol 32:859–868
89. Mendes KN, Wang GK, Fuller GN, Zhang W (2010) JNK mediates insulin-like growth factor binding protein 2/integrin alpha5-dependent glioma cell migration. Int J Oncol 37:143–153
90. Uzoh CC, Holly JM, Biernacka KM, Persad RA, Bahl A, Gillatt D, Perks CM (2011) Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel. Br J Cancer 104:1587–1593
91. Arai T, Clarke J, Parker A, Busby W Jr, Nam T, Clemmons DR (1996) Substitution of specific amino acids in insulin-like growth factor (IGF) binding protein 5 alters heparin binding and its change in affinity for IGF-I response to heparin. J Biol Chem 271:6099–6106
92. Kiepe D, Van Der Pas A, Ciarmatori S, Standker L, Schutt B, Hoeflich A, Hugel U, Oh J, Tonshoff B (2008) Defined carboxy-terminal fragments of insulin-like growth factor (IGF) binding protein-2 exert similar mitogenic activity on cultured rat growth plate chondrocytes as IGF-I. Endocrinology 149:4901–4911
93. Xi G, Solum MA, Wai C, Maile LA, Rosen CJ, Clemmons DR (2013) The heparin-binding domains of IGFBP-2 mediate its inhibitory effect on preadipocyte differentiation and fat development in male mice. Endocrinology 154:4146–4157
94. Shitara K, Yamada H, Watanabe K, Shimonaka M, Yamaguchi Y (1994) Brain-specific receptor-type protein-tyrosine phosphatase RPTP beta is a chondroitin sulfate proteoglycan in vivo. J Biol Chem 269:20189–20193
95. Sabin MA, Russo VC, Azar WJ, Yau SW, Kiess W, Werther GA (2011a) IGFBP-2 at the interface of growth and metabolism–implications for childhood obesity. Pediatr Endocrinol Rev 8:382–393
96. Nam SY, Lee EJ, Kim KR, Cha BS, Song YD, Lim SK, Lee HC, Huh KB (1997a) Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. Int J Obes Relat Metab Disord 21:355–359
97. Heald AH, Kaushal K, Siddals KW, Rudenski AS, Anderson SG, Gibson JM (2006) Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker for the metabolic syndrome. Exp Clin Endocrinol Diabetes 114:371–376
98. Li Z, Picard F (2010a) Modulation of IGFBP2 mRNA expression in white adipose tissue upon aging and obesity. Horm Metab Res 42:787–791
99. Krassas GE (2003) Endocrine abnormalities in Anorexia Nervosa. Pediatr Endocrinol Rev 1:46–54
100. Counts DR, Gwirtsman H, Carlsson LM, Lesem M, Cutler GB (1992) The effect of anorexia nervosa and refeeding on growth hormone-binding protein, the insulin-like growth factors (IGFs), and the IGF-binding proteins. J Clin Endocrinol Metab 75:762–767
101. Bereket A, Lang CH, Wilson TA (1999) Alterations in the growth hormone-insulin-like growth factor axis in insulin dependent diabetes mellitus. Horm Metab Res 31:172–181
102. Frystyk J, Bek T, Flyvbjerg A, Skjærbæk C, Ørskov H (2003) The relationship between the circulating IGF system and the presence of retinopathy in Type 1 diabetic patients. Diabet Med 20:269–276
103. Street ME, Smerieri A, Montanini L, Predieri B, Iughetti L, Valenzise M, De Luca F, Vigone M, Weber G, Maghnie M, Bernasconi S (2013) Interactions among pro-inflammatory cytokines, IGF system and thyroid function in pre-pubertal obese subjects. J Biol Regul Homeost Agents 27:259–266
104. Smerieri A, Petraroli M, Ziveri MA, Volta C, Bernasconi S, Street ME (2011) Effects of cord serum insulin, IGF-II, IGFBP-2, IL-6 and cortisol concentrations on human birth weight and length: pilot study. PLoS One 6:e29562
105. Giudice LC, de Zegher F, Gargosky SE, Dsupin BA, de las Fuentes L, Crystal RA, Hintz RL, Rosenfeld RG (1995) Insulin-like growth factors and their binding proteins in the term and preterm human fetus and neonate with normal and extremes of intrauterine growth. J Clin Endocrinol Metab 80:1548–1555
106. Ko JM, Park HK, Yang S, Hwang IT (2012) Influence of catch-up growth on IGFBP-2 levels and association between IGFBP-2 and cardiovascular risk factors in Korean children born SGA. Endocr J 59:725–733
107. de Kort SW, van Doorn J, van de Sande AG, Leunissen RW, Hokken-Koelega AC (2010) Serum insulin-like growth factor-binding protein-2 levels and metabolic and cardiovascular risk factors in young adults and children born small for gestational age. J Clin Endocrinol Metab 95:864–871
108. Friedman JM, Halaas JL (1998) Leptin and the regulation of body weight in mammals. Nature 395:763–770
109. Yau SW, Henry BA, Russo VC, McConell GK, Clarke IJ, Werther GA, Sabin MA (2014a) Leptin enhances insulin sensitivity by direct and sympathetic nervous system regulation of muscle Igfbp-2 expression - evidence from non-rodent models. Endocrinology 155:2133–2143
110. Sabin MA, Yau SW, Russo VC, Clarke IJ, Dunshea FR, Chau J, Cox M, Werther GA (2011b) Dietary monounsaturated fat in early life regulates IGFBP2: implications for fat mass accretion and insulin sensitivity. Obesity 19:2374–2381
111. Nam S, Lee E, Kim K, Cha B, Song Y, Lim S (1997b) Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. Int J Obes Relat Metab Disord 21:355–359
112. Claudio M, Benjamim F, Riccardo B, Massimiliano C, Francesco B, Luciano C (2010b) Adipocytes IGFBP-2 expression in prepubertal obese children. Obesity 18:2055–2057
113. Li Z, Picard F (2010) Modulation of IGFBP2 mRNA expression in white adipose tissue upon aging and obesity. Horm Metab Res:787–791
114. Wheatcroft S, Kearney M, Shah A, Ezzat V, Miell J, Modo M (2007b) IGF-binding protein-2 protects against the development of obesity and insulin resistance. Diabetes 56:284–294
115. Yau SW, Russo VC, Clarke IJ, Dunshea FR, Werther GA, Sabin MA (2014b) IGFBP-2 inhibits adipogenesis and lipogenesis in human visceral, but not subcutaneous, adipocytes. Int J Obes. doi:10.1038/ijo.2014.192
116. Reeve JG, Kirby LB, Brinkman A, Hughes SA, Schwander J, Bleehen NM (1992a) Insulin-like growth-factor-binding protein gene expression and protein production by human tumour cell lines. Int J Cancer 51:818–821
117. Tennant MK, Thrasher JB, Twomey PA, Birnbaum RS, Plymate SR (1996) Insulin-like growth factor-binding protein-2 and −3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. J Clin Endocrinol Metab 81:411–420
118. Wex H, Vorwerk P, Mohnike K, Bretschneider D, Kluba U, Aumann V, Blum WF, Mittler U (1998) Elevated serum levels of IGFBP-2 found in children suffering from acute leukaemia is accompanied by the occurrence of IGFBP-2 mRNA in the tumour clone. Br J Cancer 78:515–520
119. Wang H, Shen W, Huang H, Hu L, Ramdas L, Zhou YH, Liao WS, Fuller GN, Zhang W (2003) Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes. Cancer Res 63:4315–4321
120. Fukushima T, Kataoka H (2007) Roles of insulin-like growth factor binding protein-2 (IGFBP-2) in glioblastoma. Anticancer Res 27:3685–3692
121. Becher OJ, Peterson KM, Khatua S, Santi MR, MacDonald TJ (2008) IGFBP2 is overexpressed by pediatric malignant astrocytomas and induces the repair enzyme DNA-PK. J Child Neurol 23:1205–1213
122. Moore LM, Holmes KM, Smith SM, Wu Y, Tchougounova E, Uhrbom L, Sawaya R, Bruner JM, Fuller GN, Zhang W (2009) IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas. Proc Natl Acad Sci U S A 106:16675–16679
123. Fukushima T, Tezuka T, Shimomura T, Nakano S, Kataoka H (2007) Silencing of insulin-like growth factor-binding protein-2 in human glioblastoma cells reduces both invasiveness and expression of progression-associated gene CD24. J Biol Chem 282:18634–18644
124. Heinlein CA, Chang C (2004) Androgen receptor in prostate cancer. Endocr Rev 25:276–308
125. Karantanos T, Corn PG, Thompson TC (2013) Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 32:5501–5511
126. Kimura G, Kasuya J, Giannini S, Honda Y, Mohan S, Kawachi M, Akimoto M, Fujita-Yamaguchi Y (1996) Insulin-like growth factor (IGF) system components in human prostatic cancer cell-lines: LNCaP, DU145, and PC-3 cells. Intl J Urol: Off J Jpn Urol Assoc 3:39–46
127. Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR, Rosenfeld RG (1993) Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab 76:1031–1035
128. Degraff DJ, Aguiar AA, Sikes RA (2009) Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions. Am J Transl Res 1:115–130
129. Wang H, Arun BK, Wang H, Fuller GN, Zhang W, Middleton LP, Sahin AA (2008) IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas. Breast J 14:261–267
130. Juncker-Jensen A, Lykkesfeldt AE, Worm J, Ralfkiær U, Espelund U, Jepsen JS (2006) Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator. Growth Hormon IGF Res 16:224–239
131. Sohn J, Do KA, Liu S, Chen H, Mills GB, Hortobagyi GN, Meric-Bernstam F, Gonzalez-Angulo AM (2013) Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy. Ann Oncol 24:2522–2526
132. Mireuta M, Darnel A, Pollak M (2010) IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway through Sp1-induced increase in transcription. Growth Factors 28:243–255
133. Karasik A, Menczer J, Pariente C, Kanety H (1994) Insulin-like growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer. J Clin Endocrinol Metab 78:271–276
134. Kanety H, Kattan M, Goldberg I, Kopolovic J, Ravia J, Menczer J, Karasik A (1996) Increased insulin-like growth factor binding protein-2 (IGFBP-2) gene expression and protein production lead to high IGFBP-2 content in malignant ovarian cyst fluid. Br J Cancer 73:1069–1073
135. Wang H, Rosen DG, Wang H, Fuller GN, Zhang W, Liu J (2006) Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types. Mod Pathol 19:1149–1156
136. Lee EJ, Mircean C, Shmulevich I, Wang H, Liu J, Niemisto A, Kavanagh JJ, Lee JH, Zhang W (2005) Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion. Mol Cancer 4:7
137. Inaba H, Greaves M, Mullighan CG (2013) Acute lymphoblastic leukaemia. Lancet 381:1943–1955
138. Lo Nigro L (2013) Biology of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 35:245–252
139. Carroll WL, Raetz EA (2012) Clinical and laboratory biology of childhood acute lymphoblastic leukemia. J Pediatr 160:10–18
140. Rivera GK, Crist WM, Sallan SE (1994) Biology and therapy of childhood acute lymphoblastic leukemia. Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion Suppl: 26–33
141. Rodríguez-Vicente AE, Díaz MG, Hernández-Rivas JM (2013) Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease. Cancer Genet 206:49–62
142. Shanshal M, Haddad RY (2012) Chronic lymphocytic leukemia. Dis Mon 58:153–167
143. Hillmen P (2011) Using the biology of chronic lymphocytic leukemia to choose treatment. ASH Educ Program Book 2011:104–109
144. Estey EH (2013) Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol 88:317–327
145. Puumala SE, Ross JA, Aplenc R, Spector LG (2013) Epidemiology of childhood acute myeloid leukemia. Pediatr Blood Cancer 60:728–733
146. Gamis AS, Alonzo TA, Perentesis JP, Meshinchi S, COGAMLC (2013) Children’s Oncology Group’s 2013 blueprint for research: Acute myeloid leukemia. Pediatr Blood Cancer 60:964–971
147. Jabbour E, Kantarjian H (2012) Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. Am J Hematol 87:1037–1045
148. Maru Y (2012) Molecular biology of chronic myeloid leukemia. Cancer Sci 103:1601–1610
149. Zhang Y, Rowley JD (2011) Chronic myeloid leukemia: current perspectives. Clin Lab Med 31:687–698
150. Mohnike KL, Kluba U, Mittler U, Aumann V, Vorwerk P, Blum WF (1996) Serum levels of insulin-like growth factor-I, −II and insulin- like growth factor binding proteins −2 and −3 in children with acute lymphoblastic leukaemia. Eur J Pediatr 155:81–86
151. Dawczynski K, Kauf E, Zintl F (2003) Changes of serum growth factors (IGF-I,-II and IGFBP-2,-3) prior to and after stem cell transplantation in children with acute leukemia. Bone Marrow Transplant 32:411–415
152. Elmlinger MW, Wimmer K, Biemer E, Blum WF, Ranke MB, Dannecker GE (1996) Insulin-like growth factor binding protein 2 is differentially expressed in leukaemic B- and T-cell lines. Growth Regul 6:152–157
153. Attard-Montalto SP, Camacho-Hübner C, Cotterill AM, D’Souza-Li L, Daley S, Bartlett K, Halliday D, Eden OB (1998) Changes in protein turnover, IGF-I and IGF binding proteins in children with cancer. Acta Paediatr 87:54–60
154. Vorwerk P, Mohnike K, Wex H, Rohl FW, Zimmermann M, Blum WF, Mittler U (2005) Insulin-like growth factor binding protein-2 at diagnosis of childhood acute lymphoblastic leukemia and the prediction of relapse risk. J Clin Endocrinol Metab 90:3022–3027
155. Dawczynski K, Kauf E, Schlenvoigt D, Gruhn B, Fuchs D, Zintl F (2006) Elevated serum insulin-like growth factor binding protein-2 is associated with a high relapse risk after hematopoietic stem cell transplantation in childhood AML. Bone Marrow Transplant 37:589–594
156. Hattori H, Matsuzaki A, Suminoe A, Koga Y, Tashiro K, Hara T (2006) Identification of novel genes with prognostic value in childhood leukemia using cDNA microarray and quantitative RT-PCR. Pediatr Hematol Oncol 23:115–127
157. Dawczynski K, Steinbach D, Wittig S, Pfaffendorf N, Kauf E, Zintl F (2008) Expression of components of the IGF axis in childhood acute myelogenous leukemia. Pediatr Blood Cancer 50:24–28
158. Kuhnl A, Kaiser M, Neumann M, Fransecky L, Heesch S, Radmacher M, Marcucci G, Bloomfield CD, Hofmann WK, Thiel E, Baldus CD (2011) High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia. Leuk Res 35:1585–1590
159. Kitszel A, Krawczuk-Rybak M (2007) Are elevated serum levels of IGFBP-2 after intensive chemotherapy of childhood acute lymphoblastic leukemia a risk factor of relapse? Adv Med Sci 52:147–153
160. Elmlinger M, Sanatani M, Bell M, Dannecker G, Ranke M (1998) Elevated insulin-like growth factor (IGF) binding protein (IGFBP)-2 and IGFBP-4 expression of leukemic T-cells is affected by autocrine/paracrine IGF-II action but not by IGF type I receptor expression. Eur J Endocrinol 138:337–343
161. Jaques G, Kiefer P, Schoneberger HJ, Wegmann B, Kaiser U, Brandscheid D, Havemann K (1992) Differential expression of insulin-like growth factor binding proteins in human non-small cell lung cancer cell lines. Eur J Cancer 28A:1899–1904
162. Reeve JG, Brinkman A, Hughes S, Mitchell J, Schwander J, Bleehen NM (1992b) Expression of Insulinlike Growth Factor (IGF) and IGF-binding protein genes in human lung tumor cell lines. J Natl Cancer Inst 84:628–634
163. Hu Q, Huang L, Kuang X, Zhang H, Ling G, Chen X, Li K, Deng Z, Zhou J (2014) Is insulin-like growth factor binding protein 2 associated with metastasis in lung cancer? Clin Exp Metastasis 31:535–541
164. Reeve JG, Morgan J, Schwander J, Bleehen NM (1993) Role for membrane and secreted insulin-like growth factor- binding protein-2 in the regulation of insulin-like growth factor action in lung tumors. Cancer Res 53:4680–4685
165. Dong F, Wu HB, Hong J, Rechler MM (2002) Insulin-like growth factor binding protein-2 mediates the inhibition of DNA synthesis by transforming growth factor-beta in mink lung epithelial cells. J Cell Physiol 190:63–73
166. Lee DY, Kim SJ, Lee YC (1999) Serum insulin-like growth factor (IGF)-I and IGF-binding proteins in lung cancer patients. J Korean Med Sci 14:401–404
167. Guo C, Lu H, Gao W, Wang L, Lu K, Wu S, Pataer A, Huang M, El-Zein R, Lin T, Roth JA, Mehran R, Hofstetter W, Swisher SG, Wu X, Fang B (2013) Insulin-like growth factor binding protein-2 level is increased in blood of lung cancer patients and associated with poor survival. PLoS One 8:e74973
168. Yazawa T, Sato H, Shimoyamada H, Okudela K, Woo T, Tajiri M, Ogura T, Ogawa N, Suzuki T, Mitsui H, Ishii J, Miyata C, Sakaeda M, Goto K, Kashiwagi K, Masuda M, Takahashi T, Kitamura H (2009) Neuroendocrine cancer-specific up-regulating mechanism of insulin-like growth factor binding protein-2 in small cell lung cancer. Am J Pathol 175:976–987
169. Migita T, Narita T, Asaka R, Miyagi E, Nagano H, Nomura K, Matsuura M, Satoh Y, Okumura S, Nakagawa K, Seimiya H, Ishikawa Y (2010) Role of insulin-like growth factor binding protein 2 in lung adenocarcinoma: IGF-independent antiapoptotic effect via caspase-3. Am J Pathol 176:1756–1766
170. Zhang Y, Ying X, Han S, Wang J, Zhou X, Bai E, Zhang J, Zhu Q (2013) Autoantibodies against insulin-like growth factorbinding protein-2 as a serological biomarker in the diagnosis of lung cancer. Int J Oncol 42:93–100
171. Moser AR, Dove WF, Roth KA, Gordon JI (1992) The Min (multiple intestinal neoplasia) mutation: its effect on gut epithelial cell differentiation and interaction with a modifier system. J Cell Biol 116:1517–1526
172. Burgess AW (1998) Growth control mechanisms in normal and transformed intestinal cells. Philos Trans R Soc Lond Ser B Biol Sci 353:903–909
173. Rowan AJ, Lamlum H, Ilyas M, Wheeler J, Straub J, Papadopoulou A, Bicknell D, Bodmer WF, Tomlinson IPM (2000) APC mutations in sporadic colorectal tumors: A mutational “hotspot” and interdependence of the “two hits”. Proc Natl Acad Sci U S A 97:3352–3357
174. Valenta T, Hausmann G, Basler K (2012) The many faces and functions of beta-catenin. EMBO J 31:2714–2736
175. Naishiro Y, Yamada T, Idogawa M, Honda K, Takada M, Kondo T, Imai K, Hirohashi S (2005) Morphological and transcriptional responses of untransformed intestinal epithelial cells to an oncogenic [beta]-catenin protein. 24:3141–3153
176. Ben-Shmuel A, Shvab A, Gavert N, Brabletz T, Ben-Ze’ev A (2013) Global analysis of L1-transcriptomes identified IGFBP-2 as a target of ezrin and NF-[kappa]B signaling that promotes colon cancer progression. Oncogene 32:3220–3230
177. Renehan AG, Painter JE, O’Halloran D, Atkin WS, Potten CS, O’Dwyer ST, Shalet SM (2000) Circulating insulin-like growth factor II and colorectal adenomas. J Clin Endocrinol Metab 85:3402–3408
178. Mishra L, Bass B, Ooi BS, Sidawy A, Korman L (1998) Role of insulin-like growth factor-I (IGF-I) receptor, IGF-I, and IGF binding protein-2 in human colorectal cancers. Growth Horm IGF Res 8:473–479
179. el Atiq F, Garrouste F, Remacle-Bonnet M, Sastre B, Pommier G (1994) Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor-binding proteins in patients with colorectal cancer. Int J Cancer 57:491–497
180. Liou J-M, Shun C-T, Liang J-T, Chiu H-M, Chen M-J, Chen CC, Wang H-P, Wu M-S, Lin J-T (2010) Plasma insulin-like growth factor-binding protein-2 levels as diagnostic and prognostic biomarker of colorectal cancer. J Clin Endocrinol Metab 95:1717–1725
181. Miraki-Moud F, Jenkins PJ, Fairclough PD, Jordan S, Bustin SA, Jones AM, Lowe DG, Monson JP, Grossman AB, Besser GM, Camacho-Hubner C (2001) Increased levels of insulin-like growth factor binding protein-2 in sera and tumours from patients with colonic neoplasia with and without acromegaly. Clin Endocrinol (Oxford) 54:499–508
182. Ben-Shmuel A, Shvab A, Gavert N, Brabletz T, Ben-Ze’ev A (2012) Global analysis of L1-transcriptomes identified IGFBP-2 as a target of ezrin and NF-[kappa]B signaling that promotes colon cancer progression. Oncogene
183. Hoflich A, Lahm H, Blum W, Kolb H, Wolf E (1998) Insulin-like growth factor-binding protein-2 inhibits proliferation of human embryonic kidney fibroblasts and of IGF- responsive colon carcinoma cell lines. FEBS Lett 434:329–334
184. Corkins MR, Vanderhoof JA, Slentz DH, MacDonald RG, Park JH (1995) Growth stimulation by transfection of intestinal epithelial cells with an antisense insulin-like growth factor binding protein-2 construct. Biochem Biophys Res Commun 211:707–713
185. Michell NP, Langman MJ, Eggo MC (1997) Insulin-like growth factors and their binding proteins in human colonocytes: preferential degradation of insulin-like growth factor binding protein 2 in colonic cancers. Br J Cancer 76:60–66
186. Diehl D, Hessel E, Oesterle D, Renner-Muller I, Elmlinger M, Langhammer M, Gottlicher M, Wolf E, Lahm H, Hoeflich A (2009) IGFBP-2 overexpression reduces the appearance of dysplastic aberrant crypt foci and inhibits growth of adenomas in chemically induced colorectal carcinogenesis. Int J Cancer 124:2220–2225